Business Context and Reporting Period
This Form 8-K Current Report is filed by Scilex Holding Company (SCLX) for the reporting period ending December 30, 2025. The filing addresses a specific corporate transaction regarding the repurchase of warrants previously issued to Oramed Pharmaceuticals Inc.
Key Financial Metrics
The filing details a specific cash outflow related to the Warrant Repurchase transaction:
- Second Tranche Payment: $14,000,000 paid on December 30, 2025.
- First Tranche Payment: $13,000,000 paid in September 2025.
- Total Warrant Repurchase Amount: $27,000,000.
- Consideration for Option Grant: $1,500,000 previously paid to Oramed.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or overall liquidity positions for the period.
Material Changes
The material change reported is the full exercise of an option to repurchase 6,500,000 "Penny Warrants" (exercise price $0.01) issued to Oramed Pharmaceuticals Inc. on September 21, 2023. The Company completed the second and final tranche of the repurchase on December 30, 2025, effectively retiring these warrants.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general risks and contingencies beyond the specific transaction details. The document explicitly states that the information in Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the $14,000,000 cash outflow on the Company's current cash balance and liquidity.
- Confirm the removal of the 6,500,000 Penny Warrants from the Company's capital structure.
- Review the original Option Agreement dated July 22, 2025, for any remaining conditions or obligations.
- Check subsequent filings for any updated financial statements reflecting this transaction.